Evolus, Inc. (NASDAQ:EOLS) Given Consensus Rating of “Moderate Buy” by Brokerages
by Scott Moore · The Cerbat GemEvolus, Inc. (NASDAQ:EOLS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $16.00.
A number of research firms have weighed in on EOLS. HC Wainwright cut their price objective on shares of Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. BTIG Research reiterated a “buy” rating and set a $13.00 price objective on shares of Evolus in a research report on Wednesday, March 4th. Mizuho set a $15.00 price objective on shares of Evolus in a research report on Wednesday, February 4th. Wall Street Zen cut shares of Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, Weiss Ratings cut shares of Evolus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday.
Get Our Latest Stock Analysis on EOLS
Evolus Stock Down 1.5%
EOLS stock opened at $5.22 on Tuesday. Evolus has a twelve month low of $3.86 and a twelve month high of $12.28. The stock has a market capitalization of $339.61 million, a price-to-earnings ratio of -6.44 and a beta of 1.00. The firm’s fifty day simple moving average is $4.63 and its two-hundred day simple moving average is $5.65.
Evolus (NASDAQ:EOLS – Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The business had revenue of $90.30 million for the quarter, compared to analyst estimates of $89.58 million. As a group, equities research analysts expect that Evolus will post -0.43 EPS for the current year.
Insider Transactions at Evolus
In other news, insider David Moatazedi sold 116,720 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $570,760.80. Following the transaction, the insider directly owned 618,369 shares in the company, valued at approximately $3,023,824.41. This represents a 15.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Rui Avelar sold 29,996 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $146,680.44. Following the completion of the transaction, the insider owned 430,542 shares in the company, valued at approximately $2,105,350.38. The trade was a 6.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 163,504 shares of company stock worth $797,184. Company insiders own 6.10% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Rice Hall James & Associates LLC grew its holdings in shares of Evolus by 17.4% in the third quarter. Rice Hall James & Associates LLC now owns 1,168,886 shares of the company’s stock worth $7,177,000 after purchasing an additional 172,846 shares during the last quarter. Divisadero Street Capital Management LP bought a new position in shares of Evolus in the third quarter worth about $2,384,000. Squarepoint Ops LLC grew its holdings in shares of Evolus by 830.2% in the second quarter. Squarepoint Ops LLC now owns 105,797 shares of the company’s stock worth $974,000 after purchasing an additional 94,423 shares during the last quarter. American Assets Inc. bought a new position in shares of Evolus in the third quarter worth about $768,000. Finally, HighVista Strategies LLC grew its holdings in shares of Evolus by 289.4% in the third quarter. HighVista Strategies LLC now owns 226,025 shares of the company’s stock worth $1,388,000 after purchasing an additional 167,983 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.
Evolus Company Profile
Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.